Provided is a novel therapeutic agent for glaucoma, which has an sGC-activating activity. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an active ingredient, a compound represented by formula (I-a) or formula (I-b) and having a LogD value of 1.5 to 2.5 exclusive or a pharmaceutically acceptable salt of the compound. [In formulae (I-a) and (Ib), each symbol is as defined in the description.]
